Vincenzo D'Alonzo

6PUBLICATIONS
42CO-AUTHORS
Molecular targetsMedical mycologyCancer therapy (excl. chemotherapy and radiation therapy)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Oct 09, 2026
The conformation-selective PI3Kδ inhibitor roginolisib in patients with advanced or metastatic cancer, including metastatic uveal melanoma: first-in-human clinical trial.

|May 07, 2026
Circulating EV-microRNAs are dynamic biomarkers of resistance to therapeutic immunomodulation in metastatic melanoma.

|Apr 27, 2026
Tumor DNA methylation subtypes predict immunotherapy outcomes in pleural mesothelioma patients in the NIBIT-EPI-MESO study.

|Feb 13, 2026
A Real-World Experience of Cemiplimab in Patients with Advanced Cutaneous Squamous Cell Carcinoma.

Matteo Ravara, Tommaso Sani, Vincenzo D'Alonzo

|Jul 29, 2025
Biomolecular Predictors of Recurrence Patterns and Survival in IDH-Wild-Type Glioblastoma: A Retrospective Analysis of Patients Treated with Radiotherapy and Temozolomide.

Paolo Tini, Flavio Donnini, Francesco Marampon

|Dec 02, 2022
Successful Targeting of CTLA-4 in a Melanoma Clinical Case: A Long-Term "One Stop Therapeutic Shop".

Maura Colucci, Vincenzo D'Alonzo, Federica Santangelo

Pageof 1

Frequent Collaborators

3 joint publications

Anna Maria Di Giacomo

2 joint publications

Michele Maio

2 joint publications

Michele Ceccarelli

1 joint publications

Maura Colucci